Company
Aurinia Pharmaceuticals Inc.
Headquarters: Victoria, BC, Canada
Employees: 294
CEO: Mr. Peter S. Greenleaf M.B.A.
Market Cap
C$2.15 Billion
CAD as of July 1, 2021
US$1.74 Billion
Aurinia Pharmaceuticals Inc. Categories
Canada Healthcare BiotechnologyCanada Healthcare Canada Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Financials
| Last Financial Reports Date | June 30, 2021 |
| Revenue TTM | C$51.0 M |
| EBITDA | C$-126,012,000 |
| Gross Profit TTM | C$-209,000 |
| Profit Margin | -249.26% |
| Operating Margin | -250.53% |
| Quarterly Revenue Growth | 2946.70% |
Stocks & Indices
Aurinia Pharmaceuticals Inc. has the following listings and related stock indices.
Stock: TSX: AUP wb_incandescent
Stock: NASDAQ: AUPH wb_incandescent
Stock: FSX: IKAP wb_incandescent